DBV Technologies (NASDAQ:DBVT) Stock Jumps 11.2% - Time to Buy?

Key Points

• DBV Technologies shares jumped 11.2% to about $10.06 in mid-day trading, though trading volume was roughly 90% below the average session volume.
• Analyst sentiment remains generally positive: five analysts rate the stock Buy and one rates it Sell, producing a consensus “Moderate Buy” rating and a $45.25 target price. However, Guggenheim and Citizens JMP recently lowered their targets.
• The company reported a quarterly EPS loss of $0.70, missing the $0.29-loss consensus estimate, despite revenue of $1.60 million exceeding expectations. DBV remains a clinical-stage biotechnology company developing Viaskin Peanut for peanut allergies.

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) shares rose 11.2% during mid-day trading on Tuesday. The company traded as high as $9.93 and last traded at $10.0630. Approximately 32,827 shares traded hands during mid-day trading, a decline of 90% from the average session volume of 318,724 shares. The stock had previously closed at $9.05.

Analysts Set New Price Targets

DBVT has been the topic of several recent analyst reports. Guggenheim decreased their target price on shares of DBV Technologies from $51.00 to $46.00 and set a "buy" rating on the stock in a report on Friday. Citigroup restated a "market outperform" rating on shares of DBV Technologies in a research report on Thursday, October 29th. Citizens Jmp decreased their price target on DBV Technologies from $55.00 to $47.00 and set a "market outperform" rating on the stock in a research note on Thursday, October 29th. Cantor Fitzgerald reiterated an "overweight" rating on shares of DBV Technologies in a report on Thursday, September 10th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of DBV Technologies in a report on Thursday, October 15th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $45.25.

DBV Technologies Stock Performance

The company has a market cap of $630.06 million, a PE ratio of -3.32 and a beta of -1.04. The stock's 50-day simple moving average is $11.42 and its 200 day simple moving average is $16.89.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The company reported ($0.70) EPS for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.41). The firm had revenue of $1.60 million during the quarter, compared to analyst estimates of $0.56 million. DBV Technologies had a negative net margin of 5,392.17% and a negative return on equity of 115.81%. On average, sell-side analysts predict that DBV Technologies S.A. will post -2.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Vivo Capital LLC grew its stake in shares of DBV Technologies by 8.4% in the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company's stock valued at $55,726,000 after buying an additional 205,943 shares in the last quarter. ADAR1 Capital Management LLC acquired a new stake in shares of DBV Technologies in the first quarter worth $21,159,000. Perceptive Advisors LLC purchased a new position in shares of DBV Technologies during the first quarter valued at $20,146,000. Atika Capital Management LLC grew its holdings in shares of DBV Technologies by 31.1% during the first quarter. Atika Capital Management LLC now owns 271,300 shares of the company's stock valued at $5,667,000 after buying an additional 64,419 shares in the last quarter. Finally, Elmind Capital LP acquired a new position in DBV Technologies during the first quarter valued at $5,536,000. 71.74% of the stock is owned by hedge funds and other institutional investors.

DBV Technologies Company Profile

DBV Technologies SA NASDAQ: DBVT is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company's approach is based on epicutaneous immunotherapy, which is designed to deliver small amounts of an allergen through the skin to help desensitize the immune system.

DBV Technologies' lead product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.